Marcel Wacker

Tuebingen, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Loss of BECN1 does not compromise autophagosome formation but alters cargo selection and HLA-restricted antigen presentation of B cells.

Loss of BECN1 does not compromise autophagosome formation but alters cargo selection and HLA-restricted antigen presentation of B cells.

Journal: Autophagy
Published: August 21, 2026

Mouse TAPBPR shows functional similarity to human TAPBPR in shaping the MHC-I immunopeptidome.

Mouse TAPBPR shows functional similarity to human TAPBPR in shaping the MHC-I immunopeptidome.

Journal: Frontiers in immunology
Published: November 28, 2025

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

Journal: The Lancet. Haematology
Published: September 18, 2025

TAPBPR promotes editing of the HLA-B44 peptide repertoire, increasing the presentation of peptides containing a C-terminal tryptophan.

TAPBPR promotes editing of the HLA-B44 peptide repertoire, increasing the presentation of peptides containing a C-terminal tryptophan.

Journal: Frontiers in immunology
Published: August 14, 2025

PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development.

PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development.

Journal: Journal for immunotherapy of cancer
Published: March 20, 2025

MHCquant2 refines immunopeptidomics tumor antigen discovery.

MHCquant2 refines immunopeptidomics tumor antigen discovery.

Journal: Genome biology
Published: February 12, 2025

EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation.

EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation.

Journal: Cell
Published: January 30, 2025

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.

Journal: Frontiers in immunology
Published: August 18, 2024

iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.

iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.

Journal: Frontiers in oncology
Published: May 31, 2024

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.

Journal: Nature communications
Published: June 14, 2023

Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics.

Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics.

Journal: Frontiers in immunology
Published: May 09, 2023

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification.

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification.

Journal: Nature communications
Published: January 12, 2023
Showing 1-12 of 18

Last Updated: 09/26/2026